NCT05972135 2026-02-23
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
Clinical Trials
6 trialsNCT07390071 2026-02-05
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
University of Utah
Phase NA Recruiting
NCT06421675 2025-11-14
EMBRACE
Ontario Clinical Oncology Group (OCOG)
Phase 2 Recruiting
NCT04975555 2025-09-22
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
Phase 2 Active not recruiting
NCT07106671 2025-08-06
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06352866 2025-03-03
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
Case Comprehensive Cancer Center
Phase 2 Withdrawn